Home » Stocks » ICCC

ImmuCell Corporation (ICCC)

Stock Price: $10.52 USD -0.12 (-1.13%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $9.79 -0.73 (-6.94%) Feb 26, 4:27 PM
Market Cap 75.88M
Revenue (ttm) 15.23M
Net Income (ttm) -1.52M
Shares Out 7.21M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $10.52
Previous Close $10.64
Change ($) -0.12
Change (%) -1.13%
Day's Open 10.73
Day's Range 10.39 - 11.80
Day's Volume 21,497
52-Week Range 3.70 - 13.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET Conference Call Scheduled for Tuesday, February 23, 2021 at 9:00 AM ET

GlobeNewsWire - 2 months ago

PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets sc...

Seeking Alpha - 3 months ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2020 at 9:00 AM ET

GlobeNewsWire - 4 months ago

PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets sc...

Seeking Alpha - 6 months ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ET

GlobeNewsWire - 7 months ago

PORTLAND, Maine, July 07, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...

GlobeNewsWire - 8 months ago

PORTLAND, Maine, June 16, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...

Seeking Alpha - 9 months ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 9 months ago

PORTLAND, Maine, May 14, 2020 /PRNewswire/ -- ImmuCell Corporation (NASDAQ: ICCC) a growing animal health company that develops, manufactures and markets scientifically-proven and practical pr...

GlobeNewsWire - 9 months ago

PORTLAND, Maine, May 14, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (the “Company” or “ImmuCell”), a growing animal health company that develops, manufactures and markets s...

GlobeNewsWire - 10 months ago

PORTLAND, Maine, April 02, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...

GlobeNewsWire - 11 months ago

PORTLAND, Maine, March 11, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...

Seeking Alpha - 1 year ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

PORTLAND, Maine, Feb. 19, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...

GlobeNewsWire - 1 year ago

PORTLAND, Maine, Jan. 21, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets ...

Seeking Alpha - 1 year ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

PORTLAND, Maine, Sept. 17, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and marke...

GlobeNewsWire - 1 year ago

PORTLAND, Maine, Sept. 11, 2019 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”) – a growing animal health company that develops, manufactures and market...

GlobeNewsWire - 1 year ago

Second Submission Anticipated Around Q3 2020

Seeking Alpha - 1 year ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

ImmuCell Corporation's (ICCC) CEO Michael Brigham on Q1 2019 Results - Earnings Call Transcript

About ICCC

ImmuCell Corporation, an animal health company, acquires, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter o... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 1987
CEO
Michael Brigham
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
ICCC
Full Company Profile

Financial Performance

In 2019, ImmuCell's revenue was $13.72 million, an increase of 24.91% compared to the previous year's $10.99 million. Losses were -$1.30 million, -44.20% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ImmuCell stock is "Strong Buy" and the 12-month stock price forecast is 14.00.

Price Target
$14.00
Analyst Consensus: Strong Buy